Dec 16 (Reuters) - Caris Life Sciences said on Tuesday it has signed a multi-year collaboration with Genentech, part of ‌Swiss drugmaker Roche, to discover new drug targets for ‌hard-to-treat cancers.

The agreement includes $25 million in upfront and near-term payments and could bring Caris up to $1.1 billion in milestone payments tied to research, development and sales, the companies said. Sign up ...

Caris Life Sciences (CAI) has quietly outperformed in the past month, climbing about 16% even as its past 3 months remain negative. This setup invites a closer look at what investors may be repricing.

A flurry of dealmaking hasn’t let up as 2025 comes to a close, with Roche subsidiary Genentech getting in on the action and crafting a multi-year cancer collaboration with Caris Life Sciences.

This concept isn’t new—in fact, it is the essence of representational state transfer (REST). Instead of converting to a ...

Google updated its JavaScript SEO docs with new guidance on canonical URLs for JavaScript-rendered pages. Keep canonicals ...

Malicious npm package posing as a WhatsApp Web API library operated for months as a functional dependency while stealing ...

Precision medicine company Caris Life Sciences (Caris) stands behind its guiding principle of helping as many people as possible. Based in Irving, Texas, Caris leverages its clinico-genomic database, ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

A woman who crashed her car into a Center Line home and injured a 9-year-old girl had a high level of alcohol in her system, according to Macomb County prosecutors. A six-month misdemeanor charge of ...